Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy

This randomized, double-blind, placebo-controlled trial investigates coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy.

Eligible participants will be randomly assigned to receive either coenzyme Q10 or matching placebo in addition to their stable baseline anti-seizure medications. Coenzyme Q10 will be administered orally at a dose of 200 mg per day for 12 weeks.

Participants will be followed prospectively with scheduled clinical assessments throughout the study period to evaluate treatment response and safety.

Inclusion criteria

• Adults aged 20 to 80 years.
• Diagnosed with drug-resistant epilepsy.
• Receiving stable anti-seizure medications for at least 4 weeks prior to enrollment.
• Able to provide informed consent.
• Willing and able to maintain seizure diaries throughout the study period.

Exclusion criteria

• History of progressive neurological disease.
• Severe systemic illness (e.g., uncontrolled cardiovascular, hepatic, or renal disease).
• Use of coenzyme Q10 or other mitochondrial supplements within 4 weeks prior to enrollment.
• Pregnancy or breastfeeding.
• Known allergy or hypersensitivity to coenzyme Q10.
• Participation in another clinical trial within the past 3 months.